The Encore System is intended for anterior advancement of the tongue base and hyoid suspension. It is indicated for the treatment of obstructive sleep apnea (OSA) and / or snoring.

Device Description

The Encore System is designed for anterior tongue base suspension by fixation of the soft tissue of the tongue base to the mandible bone and hyoid bone suspension to the mandible bone using a bone screw and suspension lines. The Encore System consists of 1) an integrated suture passer pre-loaded with size #2-0 braided polyester suture, 2) three (3) bone screws and two (2) bone screw inserters, 3) a suspension line lock tool, 4) a threading tool, and 5) a drill bit. In addition, a #2 braided polyethelene suspension line is provided. All components are provided sterile.

AI/ML Overview

This document is a 510(k) Pre-Market Notification from the FDA regarding the Siesta Medical Encore System. It's a regulatory clearance document and does not contain the detailed study results, acceptance criteria, or performance metrics typically found in a clinical study report.

Therefore, I cannot provide the requested information, which includes a table of acceptance criteria and reported device performance, sample sizes for test and training sets, data provenance, number and qualifications of experts, adjudication methods, details of MRMC studies (effect size), standalone performance, or ground truth establishment.

The document states:

The device is the Encore™ System.
Intended Use: Anterior advancement of the tongue base and hyoid suspension for the treatment of obstructive sleep apnea (OSA) and/or snoring.
Change: The current submission (K201238) introduces a #2 braided polyethylene suspension line (vs. #2 braided polyester in the predicate K183310).
Non-Clinical Testing: A "Suture Tensile Strength Test" was conducted.
Conclusion of Testing: The results "confirmed that the strength of the #2 braided polyethylene suspension is similar to that of the existing #2 braided polyester suspension line."

This type of submission typically relies on demonstrating substantial equivalence to a predicate device, focusing on a specific change (in this case, the material of the suspension line) and ensuring that the new material does not negatively impact the device's fundamental function or safety. The "Suture Tensile Strength Test" is the evidence provided to support this claim, indicating that the new suspension line has comparable strength to the old one.

Without further documentation, it is impossible to fulfill the request for detailed study information.

Summary

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). The FDA logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA acronym along with the full name of the agency on the right. The Department of Health & Human Services logo features a stylized human figure, while the FDA part includes the acronym "FDA" in a blue square, followed by "U.S. FOOD & DRUG" and "ADMINISTRATION" in blue text.

October 2, 2020

Siesta Medical, Inc. Michael Kolber Vice President, Regulatory Affairs 101 Church Street. Suite 3 Los Gatos, California 95030

Re: K201238/S001

Trade/Device Name: Encore System Regulation Number: 21 CFR 872.5570 Regulation Name: Intraoral Devices For Snoring And Intraoral Devices For Snoring And Obstructive Sleep Apnea Regulatory Class: Class II Product Code: ORY Dated: August 31, 2020 Received: September 3, 2020

Dear Michael Kolber:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal

{1}------------------------------------------------

statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

for Srinivas "Nandu" Nandkumar, Ph.D. Director DHT1B: Division of Dental Devices OHT1: Office of Ophthalmic, Anesthesia, Respiratory, ENT and Dental Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Image /page/2/Picture/0 description: The image shows the logo for Siesta Medical. The word "Siesta" is in large, bold, black font, with a blue wave-like line above it. Below "Siesta" is the word "Medical" in a smaller, gray font. The logo is simple and modern.

Indications for Use Statement

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Indications for Use

Form Approved: OMB No. 0910-0120 Expiration Date: 06/30/2020 See PRA Statement below.

510(k) Number (if known)

Device Name

Indications for Use (Describe)

The Encore System is intended for anterior advancement of the tongue base and hyoid suspension. It is indicated for the treatment of obstructive sleep apnea (OSA) and / or snoring.

Type of Use (Select one or both, as applicable)

X Prescription Use (Part 21 CFR 801 Subpart D)

__ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

FORM FDA 3881 (7/17)

PSC Publishing Services (301) 443-6740 EF

{3}------------------------------------------------

Image /page/3/Picture/0 description: The image shows the logo for Siesta Medical. The word "Siesta" is in bold, black font, and there is a blue wave above it. Below "Siesta" is the word "Medical" in a smaller, gray font.

510(k) Summary

510(k) Number	K201238
Submitter Name and Address
Name	Siesta Medical, Inc.
Contact	Michael KolberVice President, Regulatory Affairs
Address	101 Church Street, Suite 3Los Gatos, CA 95030
Telephone	408-505-6626
Fax	408-399-7600
Date Prepared	August 31, 2020
General Device Information
Product Name	Encore™ System
Common Name	Intraoral device for snoring and obstructive sleep apnea
Classification	21CFR872.5570Intraoral devices for snoring and intraoral devices forsnoring and obstructive sleep apnea.
Device Class	Class II
Product Code	ORY

Primary Predicate DeviceManufacturer	Device Name	510(k) Number
Siesta Medical, Inc.	Encore System	K183310
Reference Predicate Device

Teleflex Medical, Inc Device Description

Manufacturer

Force Fiber Suture

K063778

Intended Use (Indications)

The Encore System is intended for anterior advancement of the tongue base and hyoid suspension. It is indicated for the treatment of obstructive sleep apnea (OSA) and /or snoring.

Comparison to the Predicate Device

The Encore System is now available with #2 braided polyethylene suspension line. It has the same intended use as the predicate device.

{4}------------------------------------------------

Image /page/4/Picture/0 description: The image shows the logo for Siesta Medical. The word "Siesta" is in bold, black font, with a blue wave-like line above it. Below "Siesta" is the word "Medical" in a smaller, light gray font. The logo is simple and modern.

The fundamental scientific technology and technological characteristics of the Encore System are the same as the predicate device including mechanism of action, packaging, biocompatibility, sterilization, and labeling. The Encore System now includes a #2 braided polyethylene suspension line and a drill bit.

Summary of Non-Clinical Testing

Performance testing was conducted to confirm that the #2 braided polyethelene suspension line has sufficuent strength to suture strength to resist breakage. A Suture Tensile Strength Test was conducted to determine the amount of force applied to the suture until the suture breaks. The results of this test confirmed that the strength of the #2 braided polyethylene suspension is similar to that of the existing #2 braided polyester suspension line.

Conclusion

Based on the intended use and technological characteristics together with results from the nonclinical performance testing, we believe that the subject device Encore System is substantially equivalent to the predicate device K183310.

Regulation Number and Section

§ 872.5570 Intraoral devices for snoring and intraoral devices for snoring and obstructive sleep apnea.

(a)
Identification. Intraoral devices for snoring and intraoral devices for snoring and obstructive sleep apnea are devices that are worn during sleep to reduce the incidence of snoring and to treat obstructive sleep apnea. The devices are designed to increase the patency of the airway and to decrease air turbulence and airway obstruction. The classification includes palatal lifting devices, tongue retaining devices, and mandibular repositioning devices.(b)
Classification. Class II (special controls). The special control for these devices is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intraoral Devices for Snoring and/or Obstructive Sleep Apnea; Guidance for Industry and FDA.”